Barclays PLC Has $529,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Barclays PLC lifted its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 279.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,580 shares of the biopharmaceutical company’s stock after buying an additional 48,316 shares during the period. Barclays PLC owned about 0.13% of Theravance Biopharma worth $529,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets grew its stake in Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after acquiring an additional 143,781 shares in the last quarter. Marshall Wace LLP grew its position in Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after purchasing an additional 135,426 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Theravance Biopharma in the 2nd quarter valued at approximately $986,000. Algert Global LLC purchased a new stake in Theravance Biopharma in the 3rd quarter worth approximately $851,000. Finally, Bank of Montreal Can boosted its stake in shares of Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after buying an additional 93,702 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Trading Down 1.4 %

Theravance Biopharma stock opened at $9.28 on Friday. The company has a market capitalization of $456.33 million, a P/E ratio of -9.19 and a beta of 0.23. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.71. The firm’s fifty day simple moving average is $9.39 and its 200-day simple moving average is $8.87.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. During the same quarter last year, the business earned ($0.17) earnings per share. On average, equities research analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares in the company, valued at $2,904,687. This trade represents a 1.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Theravance Biopharma currently has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.